Federal Circuit Splits Decision in Shockwave Medical v. CSI Balloon Catheter Patent Appeal

In a closely watched medical device patent dispute, the U.S. Court of Appeals for the Federal Circuit delivered a split decision in Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. (Case No. 23-1864), affirming the Patent Trial and Appeal Board’s (PTAB) cancellation of claims 1–4 and 6–17 of U.S. Patent No. 8,956,371, while reversing the Board’s determination on claim 5 in favor of Cardiovascular Systems, Inc. (CSI). Filed May 9, 2023, and closed July 14, 2025—after 797 days of appellate proceedings—this case underscores the high-stakes battleground surrounding intravascular lithotripsy technology and the critical importance of claim-by-claim prosecution strategy.

For patent attorneys navigating PTAB inter partes review (IPR) appeals, IP professionals tracking medical device patent litigation, and R&D teams developing competing catheter-based technologies, this outcome carries significant strategic weight. The Federal Circuit’s differentiated treatment of individual claims offers a precise roadmap for both patent assertion and invalidity defense in interventional cardiology patent disputes.

Case Overview

The Parties

The Patent at Issue

At the center of this dispute is **U.S. Patent No. 8,956,371** (Application No. 12/482,995), directed to the **Shockwave balloon catheter system**—a device designed to deliver controlled shockwave energy within a balloon catheter to disrupt arterial calcium deposits. The asserted claims cover structural and functional aspects of the IVL catheter assembly. The patentability dispute concentrated on whether these claims were anticipated or rendered obvious by prior art.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued an **affirmed-in-part and reversed-in-part** decision. Specifically:

– **Claims 1–4 and 6–17**: The Board’s determination of **unpatentability was affirmed**.
– **Claim 5**: The Board’s determination was **reversed** on CSI’s cross-appeal, meaning claim 5—previously surviving at the Board level—was found unpatentable by the Federal Circuit.

No damages were at issue, as this was a patentability/cancellation proceeding rather than a direct infringement action. The case was partially dismissed on appeal, indicating procedural narrowing during the appellate process.

Legal Significance

This decision reinforces several critical doctrinal points in medical device patent litigation:

1. Claim differentiation cuts both ways. The differential outcomes across claims 1–5 and 6–17 confirm that independent and dependent claim structures are evaluated individually.
2. PTAB deference remains high. The court’s affirmance on claims 1–4 and 6–17 under substantial evidence review illustrates the difficulty of overturning Board factual determinations on appeal.
3. Cross-appeals create real exposure. CSI’s cross-appeal succeeded in eliminating claim 5, demonstrating that respondents in PTAB appeals should aggressively pursue cross-appeal rights rather than accept partial losses.